Filtered By:
Cancer: Oral Cancer
Drug: Insulin

This page shows you your search results in order of date.

Order by Relevance | Date

Total 182 results found since Jan 2013.

Fight Aging! Newsletter, September 18th 2023
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter, please visit: https://www.fightaging.org/newsletter/ Longevity Industry Consulting Services Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out m...
Source: Fight Aging! - September 17, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Fight Aging! Newsletter, July 24th 2023
In this study, we tested the hypothesis that periodontal disease (PD) as a source of infection alters inflammatory activation and Aβ phagocytosis by the microglial cells. Experimental PD was induced using ligatures in C57BL/6 mice for 1, 10, 20, and 30 days to assess the progression of PD. Animals without ligatures were used as controls. Ligature placement caused progressive periodontal disease and bone resorption that was already significant on day 1 post-ligation and continued to increase until day 30. The severity of periodontal disease increased the frequency of activated microglia in the brains on day 30 by 36...
Source: Fight Aging! - July 23, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma
CONCLUSIONS: The combination of dasatinib 60 mg/m2/dose daily and ganitumab 18 mg/kg every two weeks was safe and tolerable. This combination had a disease control rate of 22% at five months.PMID:37398992 | DOI:10.1158/1078-0432.CCR-23-0709
Source: Clinical Cancer Research - July 3, 2023 Category: Cancer & Oncology Authors: Srivandana Akshintala R Taylor Sundby Donna Bernstein John W Glod Rosandra N Kaplan Marielle E Yohe Andrea M Gross Joanne Derdak Haiyan Lei Alexander Pan Eva Dombi Isabel Palacio-Yance Kailey R Herrera Markku M Miettinen Helen X Chen Seth M Steinberg Lee Source Type: research

Fight Aging! Newsletter, June 12th 2023
In this study, we investigated the effect of NXP032 on neurovascular stabilization through the changes of PECAM-1, PDGFR-β, ZO-1, laminin, and glial cells involved in maintaining the integrity of the blood-brain barrier (BBB) in aged mice. NXP032 was orally administered daily for 8 weeks. Compared to young mice and NXP032-treated mice, 20-month-old mice displayed cognitive impairments in Y-maze and passive avoidance tests. NXP032 treatment contributed to reducing the BBB damage by attenuating the fragmentation of microvessels and reducing PDGFR-β, ZO-1, and laminin expression, thereby mitigating astrocytes and microglia ...
Source: Fight Aging! - June 11, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Clinical and metabolic characteristics of endometrial lesions in polycystic ovary syndrome at reproductive age
CONCLUSION: Obesity, prolonged menstrual cycle, decreased SHBG, and dyslipidemia are risk factors for EH in patients with PCOS. Oral contraceptives, progestogen and metformin are recommended for prevention and treatment of endometrial lesions in PCOS patients.PMID:37149578 | DOI:10.1186/s12905-023-02339-7
Source: Cancer Control - May 6, 2023 Category: Cancer & Oncology Authors: Xiaozhu Zhong Yang Li Weiying Liang Qiyue Hu Anqi Zeng Miao Ding Dongmei Chen Meiqing Xie Source Type: research

Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer
CONCLUSIONS: In this study patients on GLM experienced worse outcomes from immunotherapy, independent of baseline features. Prospective studies are warranted to clarify the relative impact of metformin over a pre-existing diagnosis of T2DM in influencing poorer outcomes in this population.PMID:37125965 | DOI:10.1158/1078-0432.CCR-22-3116
Source: Clinical Cancer Research - May 1, 2023 Category: Cancer & Oncology Authors: Alessio Cortellini Antonio D'Alessio Siobhan Cleary Sebastiano Buti Melissa Bersanelli Paola Bordi Giuseppe Tonini Bruno Vincenzi Marco Tucci Alessandro Russo Francesco Pantano Marco Russano Luigia Stefania Stucci Maria Chiara Sergi Martina Falconi Maria Source Type: research

Fight Aging! Newsletter, April 24th 2023
In this study, researchers show that mice lacking a functional ATF4 gene show little to no loss of grip strength and treadmill performance into late life; it is quite an impressive effect size. Assessments of muscle biochemistry do show age-related declines, but to a lesser degree than the controls. How ATF4 knockout functions to produce this outcome is an interesting question. The researchers point out a range of possible downstream and upstream targets that have been implicated in the regulation of muscle growth, but it will clearly require further work to identify the important mechanisms involved. Aging slowly...
Source: Fight Aging! - April 23, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs